Effect of Ketogenic Diet on Peri-operative Complications of Right Laparoscopic Adrenalectomy in Obese Patients

Sponsor
Federico II University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05816031
Collaborator
(none)
80
1
42.4
1.9

Study Details

Study Description

Brief Summary

Ketogenic diet is often prescribed to morbid obese patients scheduled for bariatric surgery in order to reduce liver size, thus making surgery less demanding. The study aim to investigate the possible effects of ketogenic diet on intra- and peri-operative complications of right laparoscopic adrenalectomy in obese patients; researchers will analyze intra- and peri-operative outcomes among obese patients who underwent laparoscopic right adrenalectomy, comparing the two arms with and without ketogenic diet.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Ketogenic diet

Detailed Description

Ketogenic diet is often prescribed to morbid obese patients scheduled for bariatric surgery in order to reduce liver size, thus making surgery less demanding. Due to a standard trans abdominal laparoscopic right adrenalectomy is performed with the patient in left lateral position, it is necessary to retract liver in order to expose the right adrenal gland and the cava vein. It is therefore evident how a reduced size liver may allow a faster, easier and safer surgery. Finding a normal size liver is uncommon in patients presenting with a body mass index above 30 Kg/m2. According to this, patients scheduled to right laparoscopic adrenalectomy and belonging to the case arm, will be administered a standard 21 days ketogenic diet before surgery. Conversely this will not be prescribed to patients belonging to control group. Ketogenic diet is based on a standard diet plus a ketogenic product to be taken once daily for 21 days. In both groups patients will undergo abdominal ultrasound before surgery.

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Effect of Ketogenic Diet on Peri-operative Complications of Right Laparoscopic Adrenalectomy in Obese Patients
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jul 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Ketogenic diet

Patients scheduled to right laparoscopic adrenalectomy and belonging to the case arm, will be administered a standard 21 days ketogenic diet before surgery. Ketogenic diet is based on a standard diet plus a ketogenic product to be taken once daily for 21 days. In both groups patients will undergo abdominal ultrasound before surgery.

Dietary Supplement: Ketogenic diet
Ketogenic diet administrated to obese patients planned for right laparoscopic adrenalectomy

No ketogenic diet

Ketogenic diet will not be prescribed to patients belonging to control group.

Outcome Measures

Primary Outcome Measures

  1. Peri-operative complications [Complications occurring during surgery and within 30 days from surgery]

    Pre and post-operative (within 30 days) complications of laparoscopic adrenalectomy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • BMI > 30 Kg/m2

  • Planned for laparoscopic right adrenalectomy

  • Age > 18y.o.

  • No contraindications for ketogenic diet

Exclusion Criteria:
  • Diabetes

  • Patients requiring conversion to open surgery

  • BMI < 30 Kg/m2

  • Age < 18 y.o.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nunzio Velotti Naples Italy 80131

Sponsors and Collaborators

  • Federico II University

Investigators

  • Principal Investigator: Mario Musella, Federico II University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mario Musella MD, Professor, Federico II University
ClinicalTrials.gov Identifier:
NCT05816031
Other Study ID Numbers:
  • KetoAdreno
First Posted:
Apr 18, 2023
Last Update Posted:
Apr 18, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 18, 2023